41st week of 2008 patent applcation highlights part 33 |
Patent application number | Title | Published |
20080248001 | METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS - Methods for the treatment of a cell proliferation disorder in a subject, involving:
| 2008-10-09 |
20080248002 | ANTI-ANGIOGENIC CELLULAR AGENT FOR CANCER THERAPY - The invention provides cytokine induced killer (CIK) cell populations and methods of using CIK cells to treat cellular proliferative disorders. CIK cells generated in vitro include both bulk cultures and clones. Individual CIK cell clones display distinct but overlapping lytic specificities for tumor cells and endothelial cells in vitro. When injected in vivo, bulk CIK cell cultures selectively attack tumor tissue. CIK cells can be used to treat a variety of cellular proliferative disorders, including early and late stage cancers as well as hematopoietic cell and solid tissue tumors. | 2008-10-09 |
20080248003 | Methods and Compositions for Growing Adipose Stem Cells - The present invention relates to adipose tissue-derived stem cells and to methods and compositions for enhancing growth and differentiation of such cells. The invention further relates to growing such cells in serum-free or low serum growth medium, and formulations thereof. | 2008-10-09 |
20080248004 | Cell fractions containing cells capable of differentiating into neural cells - Demyelinated axons were remyelinated in the demyelinated rat model by collecting bone marrow cells from mouse bone marrow and transplanting the mononuclear cell fraction separated from these bone marrow cells. | 2008-10-09 |
20080248005 | Isolation and Cultivation of Stem/Progenitor Cells From the Amniotic Membrane of Umbilical Cord and Uses of Cells Differentiated Therefrom - The present invention relates to a skin equivalent and a method for producing the same, wherein the skin equivalent comprises a scaffold and stem/progenitor cells isolated from the amniotic membrane of umbilical cord. These stem/progenitor cells may be mesenchymal (UCMC) and/or epithelial (UCEC) stem cells, which may then be further differentiated to fibroblast and keratinocytes. Further described is a method for isolating stem/progenitor cells from the amniotic membrane of umbilical cord, wherein the method comprises separating the amniotic membrane from the other components of the umbilical cord in vitro, culturing the amniotic membrane tissue under conditions allowing cell proliferation, and isolating the stem/progenitor cells from the tissue cultures. The invention also refers to therapeutic uses of these skin equivalents. Another aspect of the invention relates to the generation of a mucin-producing cell using stem/progenitor cells obtained from the amniotic membrane of umbilical cord and therapeutic uses of such mucin-producing cells. In yet another aspect, the invention relates to a method for generating an insulin-producing cell using stem/progenitor cells isolated from the amniotic membrane of umbilical cord and therapeutic uses thereof. The invention further refers to a method of treating a bone or cartilage disorder using UCMC. Furthermore, the invention refers to a method of generating a dopamin and tyrosin hydroxylase as well as a HLA-G and hepatocytes using UCMC and/or UCEC. The present invention also refers to a method of inducing proliferation of aged keratinocytes using UCMC. | 2008-10-09 |
20080248006 | Process For Ex Vivo Formation of Mammalian Bone And Uses Thereof - The present invention concerns methods for the ex vivo formation of mammalian bone and subsequent uses of the bone. A critical and distinguishing feature of the present invention are defined tissue culture conditions and factors resulting in the formation of bone cell spheroids. The invention also provides for methods of implanting into subjects the ex vivo formed bone. Also described are methods for genetically altering the bone cell spheroids to affect bone formation, identification of candidate modulators of bone formation, and identification of genes involved in bone formation. | 2008-10-09 |
20080248007 | B7-H5, A Costimulatory Polypeptide - B7-HS costimulatory polypeptides, nucleic acids encoding such polypeptides, and methods for using the polypeptides and nucleic acids to enhance a T cell response are provided herein. | 2008-10-09 |
20080248008 | Inhibitors of Protein Kinase a Anchoring - A PKA I anchoring disrupting molecule or AKAP mimic, wherein said molecule or mimic is a polypeptide which comprises the following amino acid sequence: X | 2008-10-09 |
20080248009 | REGULATION OF ACHERON EXPRESSION - The invention relates to novel apoptosis-associated nucleic acids and polypeptides and methods for use thereof, including methods of treatment of disorders associated with aberrant cellular proliferation, differentiation, or degeneration. Included are methods of enhancing the success of cell transplantation and cell-based genetic therapy procedures. | 2008-10-09 |
20080248010 | Compositions and methods of using apoptosis signaling kinase related kinase (ASKRK) - The invention provides apoptosis signaling kinase related kinase (ASKRK) nucleic acid and polypeptide sequences and methods of using such sequences to identify modulators of ASKRK. Such modulators can be used for the treatment of diabetes or for delaying the onset of diabetes. The invention also provides methods of diagnosing diabetes or pre-diabetes and methods of making a prognosis based on the detection of ASKRK nucleic acids and proteins. | 2008-10-09 |
20080248011 | Methods for Isolating Monocytes - The present invention provides HIDE1 as novel monocyte markers. Since HIDE1 are membrane proteins, monocytes can be specifically detected by using antibodies that bind to HIDE1. Further, HIDE1-positive monocytes can also be collected from peripheral blood or the like using a cell sorter, magnet, or such. Monocytes that can be prepared based on the present invention are useful in cell immunotherapy. | 2008-10-09 |
20080248012 | Erythrocyte Function Modifying Substance - A promoter of ATP release from red blood cells, comprising a substance capable of stabilizing the structure of hemoglobin in red blood cells in its T-state; and a method of releasing ATP from red blood cells with the use of the promoter. There are further provided an inhibitor of ATP release from red blood cells, comprising a substance capable of stabilizing the structure of hemoglobin in red blood cells in its R-state; and a method of inhibiting ATP release from red blood cells with the use of the inhibitor. | 2008-10-09 |
20080248013 | Coenzyme Q10- Containing Composition - There is provided a coenzyme Q | 2008-10-09 |
20080248014 | Animal Medicament and Method of Manufacture - A medicament for administration to a non-human animal, wherein the medicament includes at Least partially hydrolysed protein and one or more pharmacologically active substances. In a preferred embodiment, the protein is derived from meat which is hydrolysed using a fruit-derived proteolytic enzyme such as actinidin from kiwifruit which enhances the palatability of the resulting hydrolysate. A method of manufacturing the medicament, and a method of medicating a non-human animal by administering to the animal a medicament are also disclosed. | 2008-10-09 |
20080248015 | METHODS AND KITS FOR CO-ADMINISTRATION OF NUTRITIONAL SUPPLEMENTS - The present invention relates to methods of co-administration of various vitamin and mineral compositions, and in a specific embodiment, comprise co-administering one composition comprising vitamin B | 2008-10-09 |
20080248016 | Novel Iaccase Enzymes and Their Uses - The present invention relates to novel laccase enzymes obtainable from the strains of the genus | 2008-10-09 |
20080248017 | METHODS AND DEVICES FOR THE SUSTAINED RELEASE OF MULTIPLE DRUGS - The invention relates to an drug delivery device and a method for delivering multiple drugs over a prolonged period of time. The drug delivery device has two or more unitary segments comprising a drug-permeable polymeric substance, wherein at least one of the segments further comprises a pharmaceutically active agent. The invention also relates to a method for the treatment of a benign ovarian secretory disorder in a female mammal, a method of contraception, and a method of relieving the symptoms associated with menopausal, perimenopausal and post-menopausal periods in a woman. | 2008-10-09 |
20080248018 | PHARMACEUTICAL PREPARATION AND METHOD OF TREATMENT OF HUMAN MALIGNANCIES WITH ARGININE DEPRIVATION - The present invention provides an isolated and substantially purified recombinant human arginase having sufficiently high enzymatic activity and stability to maintain Adequate Arginine Depletion in a patient. The present invention also provides a pharmaceutical composition comprising the modified invention enzyme and method for treatment of diseases using the pharmaceutical composition. | 2008-10-09 |
20080248019 | Recombinant beta-galactosidase derived from Streptococcus pneumaniae - The present invention relates to a novel beta-galactosidase derived from | 2008-10-09 |
20080248020 | Heparanases and Splice Variants Thereof, Ponucleotides Encoding Them and Uses Thereof - The invention relates to novel heparanases, heparanase splice variants, and to polynucleotides encoding them. Particularly, the invention relates to | 2008-10-09 |
20080248021 | Use of Hyaluronidase in Combination with Plasmin for the Induction of Posterior Vitreous Detachment - The present invention is directed to compositions and processes related to use of hyaluronidase in combination with plasmin for the induction of posterior vitreous detachment. | 2008-10-09 |
20080248022 | Therapeutic Strategy for Treating Autoimmune and Degenerative Diseases - Numerous diseases have been linked to the production of effector cells. The present invention relates to the realization that effector cells are cycling in these diseases. In addition, the present invention relates to the determination that regulator cells are cycling in degenerative diseases. Based on these realizations, the present invention provides methods for treating conditions such as autoimmune diseases, degenerative diseases, and graft-versus-host disease. The present invention also relates to methods of determining when therapy should be administered to a patient. | 2008-10-09 |
20080248023 | PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASES - Disclosed are pharmaceutical compositions and methods for preventing or treating a number of amyloid diseases, including Alzheimer's disease, prion diseases, familial amyloid neuropathies and the like. The pharmaceutical compositions include immunologically reactive amounts of amyloid fibril components, particularly fibril-forming peptides or proteins. Also disclosed are therapeutic compositions and methods which use immune reagents that react with such fibril components. | 2008-10-09 |
20080248024 | THERAPEUTIC AGENT FOR CANCER, INFLAMMATION, AND AUTO-IMMUNE DISEASE CONTAINING INHIBITOR OF ZINC FINGER PROTEIN 91 - The present invention relates to a use of ZFP91 based on the functions of ZFP91 (Zinc Finger Protein 91) and the interaction of ZFP91 with NF-κB (Nuclear factor kappa B) signal transduction pathway proteins, more precisely a method to inhibit the activation of NF-κB alternative pathway by regulating ZFP91 activation, to inhibit tumor growth by inhibiting the transcription factor HIF-1 (hypoxia inducible factor-1) activation, to inhibit cancer malignancy by inhibiting angiogenesis, or reversely a method to increase the activation of NF-κB alternative pathway or to increase angiogenesis by increasing activation of HIF-1. The method of regulating ZFP91 activation of the present invention can increase or reduce HIF-1α stability by increasing or reducing the activation of NF-κB alternative pathway, so that it can be effectively used for the development of an anticancer agent, a therapeutic agent for arthritis, a therapeutic agent for ulcerative colitis, an anti-inflammatory agent and an angiogenesis inducer. | 2008-10-09 |
20080248025 | Gamma Delta T Cells and Methods of Treatment of Interleukin-17 Related Conditions - This invention generally relates to methods to treat conditions and diseases associated with interleukin-17 (IL-17) production. The invention also relates to methods of inhibiting γδ T cells, and particularly, a subset of γδ T cells that produce IL-17. | 2008-10-09 |
20080248026 | PTEN/Akt methods and compositions relating to BMP - The present invention relates to a purified molecules, including antibodies, that bind specifically to murine β-catenin phosphorylated at amino acid position Serine | 2008-10-09 |
20080248027 | Method of enhancing intestinal pinocytosis of immunoglobulins in postnatal domestic mammals - Disclosed is a method of enhancing absorption (pinocytosis efficiecy) of immunoglobulins administered to postnatal domestic mammals (e.g., bovine) by using selenium. As an example of a selenium compound added, sodium selenite is particularly effective. | 2008-10-09 |
20080248028 | Immunoglobulin Variants Outside the Fc Region - The present invention relates to antibody variants outside the Fc region that alter binding affinity to one or more effector ligands, methods for their generation, and their therapeutic application. | 2008-10-09 |
20080248029 | PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASES - Disclosed are pharmaceutical compositions and methods for preventing or treating a number of amyloid diseases, including Alzheimer's disease, prion diseases, familial amyloid neuropathies and the like. The pharmaceutical compositions include immunologically reactive amounts of amyloid fibril components, particularly fibril-forming peptides or proteins. Also disclosed are therapeutic compositions and methods which use immune reagents that react with such fibril components. | 2008-10-09 |
20080248030 | Method of Treating Angiogenic Diseases - The present invention relates to methods for treating cancer comprising administering an anti-VEGF (vascular endothelial growth factor) monoclonal antibody (e.g. Avastin) and a N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-TNP-470 conjugate (e.g. Caplostatin) to a patient in need thereof. | 2008-10-09 |
20080248031 | CELL SURFACE MOLECULE MEDIATING CELL ADHESION AND SIGNAL TRANSMISSION - Novel cell surface molecules recognized by monoclonal antibodies against a cell surface molecule of lymphocytic cells that play an important role in autoimmune diseases and allergic diseases have been isolated, identified, and analyzed for their functions. The cell surface molecules are expressed specifically in thymocytes, lymphocytes activated by ConA-stimulation, and peripheral blood lymphocytes, and induce cell adhesion. Antibodies against the cell surface molecules significantly ameliorate pathological conditions of autoimmune diseases and allergic diseases. | 2008-10-09 |
20080248032 | COMPOSITIONS AND METHODS FOR PROTECTION AGAINST CARDIAC AND/OR CENTRAL NERVOUS SYSTEM TISSUE INJURY BY INHIBITING SPHINGOSINE-1-PHOSPHATE LYASE - The present invention relates generally to the prevention and/or treatment of cardiac and stroke injury. In particular, the present invention provides compositions and methods for preventing and treating tissue injury in cardiac and stroke settings and injury due to ischemia/reperfusion, hypoxia, cardiotoxicity of certain therapeutic regimens, and other causes, by administering an agent that inhibits sphingosine-1-phosphate lyase (SPL) activity. | 2008-10-09 |
20080248033 | VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors - Disclosed herein are methods of treating benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating a subject at risk of developing benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating or preventing recurrence of a tumor using an anti-VEGF-specific antagonist as well as use of VEGF-specific antagonists in neoadjuvant and adjuvant cancer therapy. | 2008-10-09 |
20080248034 | Methods For Inhibiting The Binding Of Endosialin To Ligands - The invention provides methods for inhibiting the interaction of endosialin with endosialin ligands. The inhibition is effectuated on the genetic level, by inhibiting endosialin gene expression, and on the protein level, by blocking the interaction of cell-surface expressed endosialin with ligands such as fibronectin and collagen. The invention provides methods for identifying inhibitors of the interaction of endosialin with endosialin ligands. Also provided are methods for inhibiting angiogenesis and neovascularization in vivo and in vitro. | 2008-10-09 |
20080248035 | Pharmaceutical Combination - This invention relates to a combination product or medicament comprising at least one novel substituted pyrrole derivative and one or more dyslipidemic agents, antiobesity agents, antihyperglycaemic agents, anti-inflammatory agents or mixture thereof. Also provided herein are the pharmaceutical compositions comprising at least one novel substituted pyrrole derivative and one or more dyslipidemic agents, antiobesity agents, antihyperglycaemic agents, anti-inflammatory agents or mixture thereof and optionally together with at least one pharmaceutically acceptable carrier, and methods for the treatment or prophylaxis of cardiovascular diseases, Alzheimer's disease, obesity, diabetes or inflammatory diseases comprising administering to a mammal in need thereof therapeutically effective amounts of combination pharmaceutical composition comprising at least one novel substituted pyrrole derivative and one or more dyslipidemic agents, antiobesity agents, antihyperglycaemic agents, anti-inflammatory agents or mixtures thereof. | 2008-10-09 |
20080248036 | TREATMENT WITH ANTI-VEGF ANTIBODIES - This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents. | 2008-10-09 |
20080248037 | Dr5 Antibodies and Uses Thereof - The application provides antibodies which specifically bind to DR5 receptor. The anti-DR5 antibodies optionally contain CDR sequences identified using phage-display techniques. The DR5 antibodies can be used, for example, in methods where a modulation of the biological activities of Apo-2L and/or Apo-2L receptors is desired, including cancer and immune-related conditions. | 2008-10-09 |
20080248038 | Combination of an anti ED-B fibronectin domain antibody and an anti-EGFR-antibody - The invention relates to a combination (i) of a fusion protein, comprising an ε | 2008-10-09 |
20080248039 | Antibodies Against Histone Modifications for Clinical Diagnosis and Prognosis of Cancer - The present invention provides methods of diagnosing and providing a prognosis for a cancer by identifying cancers with altered global histone modification patterns using immunohistochemical techniques. | 2008-10-09 |
20080248040 | Nucleic Acid Molecules Encoding Novel Human Low-Voltage Activated Calcium Channel Proteins, Designed-Alpha 1I-1 and Alpha 1I-2, Encoded Proteins and Methods of Use Thereof - Disclosed are mammalian nucleic acid sequences encoding α1I subunit isoforms of a voltage-gated calcium channel. Specifically disclosed are novel variants of the α1I subunit designated herein as α1I-1 and α1I-2. In other aspects, the disclosure relates to expression vectors which encode the novel subunits of the invention, as well as cells containing such vectors. Antibodies specific for each of the variant subunits are also provided. The nucleic acid sequences of the invention find application, for example, in screening for compounds which modulate the activity of voltage-gated calcium channels and also in diagnostic methods for diagnosing various T-type channel mediated disorders, e.g., epilepsy, cancer, pain, sleep disorders and the autoimmune disease Lambert-Eaton Syndrome. Diagnosing defects in α1I subunit genes of a patient with a neuronal disease such as epilepsy are also included. An additional application of the nucleic acid sequences of the invention is in therapeutic methods of treatment for α1I subunit mediated disorders. | 2008-10-09 |
20080248041 | Novel Ligands for G Protein-Coupled Receptor Protein and Use Thereof - The present invention provides a method of screening an agonist/antagonist of a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, which comprises using the receptor protein or its salt and a ligand or its salt; and so on. The screening method of the present invention is useful for screening an agent for the prevention/treatment of nervous system diseases or neuropathic pains. | 2008-10-09 |
20080248042 | Monoclonal antibody cross-reactive against infective agent causing a B-cell expansion and IgG-Fc - This invention disclosed a monoclonal antibody or a derivative thereof which is cross-reactive against the immunogenic sequence of an infective agent causing a B-cell expansion and IgG-Fc, said infective agent is selected from the group consisting of | 2008-10-09 |
20080248043 | Antibodies to SARS coronavirus - The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to human SARS-CoV S protein, and that function to neutralize SARS-CoV. The invention also relates to antibodies that are bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-SARS-CoV S protein antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-SARS-CoV S protein antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention. | 2008-10-09 |
20080248044 | POLYEPITOPIC PROTEIN FRAGMENTS OF THE E6 AND E7 PROTEINS OF HPV, THEIR PRODUCTION AND THEIR USE PARTICULARLY IN VACCINATION - Polyepitopic peptides of E6 and E7 proteins of Human Papillomavirus, their production, and methods of treating pathologies in which a polyepitopic peptide of the E6 and E7 protein of Human Papillomavirus is recognized by the cellular immune system. | 2008-10-09 |
20080248045 | POLYPEPTIDES HAVING A TRIGGERING NK ACTIVITY AND BIOLOGICAL APPLICATIONS - The invention relates to polypeptides having a triggering NK activity and an amino acid sequence that is at least 80% identical over its entire length to the polypeptide having SEQ ID NO: 1, and any immunogenic fragments thereof, as well as to the polyclonal and monoclonal antibodies directed against said polypeptides, and immuno-reactive fragments thereof. Application for detecting NK cells in a sample, for their removal from a sample or for enrichment of NK cells, and for NK cell natural cytotoxicity regulation. | 2008-10-09 |
20080248046 | Death domain containing receptor 5 - The present invention relates to novel Death Domain Containing Receptor-5 (DR5) proteins which are members of the tumor necrosis factor (TNF) receptor family, and have now been shown to bind TRAIL. In particular, isolated nucleic acid molecules are provided encoding the human DR5 proteins. DR5 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying antagonists and antagonists of DR5 activity. The invention also relates to the treatment of diseases associated with reduced or increased levels of apoptosis using antibodies specific for DR5, which may be agonists and/or antagonists of DR5 activity. | 2008-10-09 |
20080248047 | Platform Antibody Compositions - The present invention provides novel compositions of human IgG | 2008-10-09 |
20080248048 | Interleukin-13 Antibody Composition - The invention relates to a pharmaceutical composition comprising an interleukin-13 antibody, more particularly a monoclonal interleukin-13 antibody, especially a human interleukin-13 monoclonal antibody, to a process for purifying said antibody and to the use of said composition in treating interleukin-13 related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, chronic obstructive pulmonary disease, scleroderma, inflammatory bowel disease and Hodgkin's lymphoma, particularly asthma. | 2008-10-09 |
20080248049 | TREATMENT WITH ANTI-VEGF ANTIBODIES - This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents. | 2008-10-09 |
20080248050 | Meta-specific vaccine, method for treating patients immunized with meta-specific vaccine - A meta-specific vaccine particle is provided. Also provided is a method for inducing an immune response in a human ( | 2008-10-09 |
20080248051 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS - Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo. | 2008-10-09 |
20080248052 | Multi-Drug Ligand Conjugates - Described herein are compounds, pharmaceutical compositions and methods for treating pathogenic cell populations in a patient. The compounds described herein include conjugates of a plurality of cytotoxic drugs and vitamin receptor binding ligands. The plurality of drugs may be the same or different. Similarly, the vitamin receptor binding ligands may be the same or different. The conjugates also include a linker that is formed from one or more spacer linkers, heteroatom linkers, and releasable linkers. | 2008-10-09 |
20080248053 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS - Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo. | 2008-10-09 |
20080248054 | Regulation of Mink in Thymocytes and T Lymphocytes - The invention relates to compositions and methods used to assess and alter the expression and activity of MINK in cells of the immune system, particularly thymocytes and T lymphocytes. The methods and compositions are used in a variety of clinical applications including vaccination, treatment of cancer, infectious disease, allergy, and transplantation. Screening methods are provided to identify inhibitors of MINK and susceptibility to effects of under- or over-expression of MINK. | 2008-10-09 |
20080248055 | Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes - The present invention regards methods and formulations for the treatment of diabetes and the prevention of autoimmune diabetes. The invention includes the administration of human recombinant GAD65 protein in a pharmaceutically acceptable adjuvant. | 2008-10-09 |
20080248056 | Immunomodulatory Product Obtained from a Bifidobacterium Culture and Compositions Containing the Same - The invention relates to an immunomodulatory product obtained from a | 2008-10-09 |
20080248057 | Multivalent immunogenic composition containing RSV subunit compostion and influenza virus preparation - Immunogenic compositions for administration to adults particularly to the elderly, to protect them against disease caused by infection by respiratory syncytial virus and influenza virus comprise an immunoeffective amount of a mixture of purified fusion (F) protein, attachment (G) protein and matrix (M) protein of RSV and an immunoeffective amount of a non-virulent influenza virus preparation. The components of the composition when formulated as a vaccine for in vivo administration do not impair the immunogenicity of each other. The immunogenic composition may also contain an adjuvant. | 2008-10-09 |
20080248058 | Plant Disease Control Agent And Method For Controlling Plant Disease - The present invention provides a plant disease control agent which is stable and safe in terms of leaving no residue and a method for controlling plant diseases using the same. The plant disease control agent comprises a fragment of an inky cap mushroom, and plant diseases are controlled by using the plant disease control agent. The plant disease control agent may be a suspension comprising the fragment of the inky cap mushroom or a solid material composed of the suspension and a carrier to which the suspension is absorbed. The inky cap mushroom is preferably | 2008-10-09 |
20080248059 | Dimensional Analysis of Saccharide Conjugates with Gpc & Sec-Mals - GPC (gel permeation chromatography) and size exclusion chromatography with detection by multi-angle light scattering photometry (SEC-MALS) can be used to accurately measure molecular size and molar mass, respectively, of saccharide conjugates. The invention provides (a) a process for measuring the molecular size of a conjugated saccharide antigen within a sample, comprising a step of analyzing the sample by GPC, and (b) a process for measuring the molar mass of a conjugated saccharide antigen within a sample, comprising a step of analysing the sample by SEC-MALS. | 2008-10-09 |
20080248060 | ADENOVIRAL VECTOR-BASED MALARIA VACCINES - The invention provides a method of inducing an immune response against malaria in a mammal. The method comprises intramuscularly administering to a mammal a composition comprising a pharmaceutically acceptable carrier and either or both of (a) a first adenoviral vector comprising a nucleic acid sequence encoding a | 2008-10-09 |
20080248061 | Pcv-2 Vaccine - The present invention relates to a vaccine against porcine circovirus type 2 (PCV-)2 and a method for the manufacture of such a vaccine, for protecting piglets against PCV-2 infection. | 2008-10-09 |
20080248062 | Papillomavirus vaccine compositions - The present invention relates to pharmaceutical compositions comprising virus-like particles (VLPs) of HPV, said VLPs adsorbed to an aluminum adjuvant, and an ISCOM-type adjuvant comprising a saponin, cholesterol, and a phospholipid. In preferred embodiments, the aluminum adjuvant comprises amorphous aluminum hydroxyphosphate sulfate. Another aspect of the invention provides multi-dose HPV vaccine formulations comprising HPV VLPs and an antimicrobial preservative selected from the group consisting of: m-cresol, phenol and benzyl alcohol. Also provided are methods of using the disclosed pharmaceutical compositions and formulations to induce an immune response against HPV in a human patient and to prevent HPV infection. | 2008-10-09 |
20080248063 | Hetero-Oligomeric Hiv Envelope Proteins - In one aspect, the invention provides an HIV envelope heterotrimer comprising at least two different Env glycoprotein monomers. In some heterotrimers, at least two Env glycoprotein monomers are from different HIV isolates, for example, different HIV-1 isolates. Heterotrimers may contain Env glycoprotein monomers from HIV isolates belonging to the same clade or to different clades or both. At least one of the Env glycoprotein monomers in a heterotrimer of the invention may be modified in a way that alters its amino acid composition. In another aspect, the invention provides methods for inducing an immune response in a vertebrate host against HIV or an HIV-infected cell, comprising administering to a vertebrate host a prophylactically or therapeutically effective amount of a composition comprising an HIV envelope heterotrimer. | 2008-10-09 |
20080248064 | Localization and Characterization of Flavivirus Envelope Gylcoprotein Cross-Reactive Epitopes and Methods for their Use - Disclosed herein is a method for identifying flavivirus cross-reactive epitopes. Also provided are flavivirus E-glyco-protein cross-reactive epitopes and flavivirus E-glycoprotein crossreactive epitopes having reduced or ablated cross-reactivity (and polypeptides comprising such epitopes), as well as methods of using these molecules to elicit an immune response against a flavivirus and to detect a flaviviral infection. | 2008-10-09 |
20080248065 | Gna1870-Based Vesicle Vaccines for Broad Spectrum Protection Against Diseases Caused by Neisseria Meningitidis - The present invention generally provides methods and compositions for eliciting an immune response against | 2008-10-09 |
20080248066 | Modified free-living microbes, vaccine compositions and methods of use thereof - Free-living microbes are provided in which the nucleic acid has been modified so that the microbe is attenuated for proliferation and/or which comprise genetic mutations that attenuate the ability of the microbe to repair its nucleic acid. Methods of using the modified microbes for the loading, activation, and/or maturation of antigen-presenting cells are also provided. Vaccine compositions comprising the modified microbes and/or the antigen-presenting cells and methods of using the vaccines are also provided. The microbes may be further modified to include heterologous antigens, such as tumor antigens or infectious disease antigens, for use as a vaccine against cancer or infectious diseases. | 2008-10-09 |
20080248067 | Immunomodulating Compositions and Uses Therefor - The present invention discloses the use of an inhibitor of IL-10 function and an immune stimulator that stimulates the priming of an immune response to a target antigen, in methods and compositions for stimulating and prolonging host immune responses to the target antigen. The methods and compositions of the present invention are particularly useful in the treatment or prophylaxis of a range of conditions including pathogenic infections and cancers. | 2008-10-09 |
20080248068 | Use of Flagellin as an Adjuvant for Vaccine - The present invention is directed to flagellin and its use as an adjuvant for vaccination. The invention can be used in vaccine formulations to improve immunity against any other antigen administered at the same localization. The antigen can be administered in the same construct as Flagellin or in any other formulation given at the same localization. As an alternative flagellin can be used to stimulate immunity against antigens expressed at a specific location. Flagellin can also be used to induce local inflammation with the purpose of creating a model for inflammation. | 2008-10-09 |
20080248069 | Dosage Forms of Active Ingredients Containing Hydroxystilbene for Treating Menopausal Complaints - The invention relates to novel dosage forms containing hydroxystilbene, to a method for producing said dosage forms and to their use for treating female menopausal complaints, juvenile oligomenorrhoea and dysmenorrhoea, primary and secondary amenorrhoea or endometritis. | 2008-10-09 |
20080248070 | HDL-Boosting Combination Therapy Complexes - A pharmaceutical composition including therapeutically effective amounts of at least one HMG-CoA reductase inhibitor present as a dyhydroxyacid salt and at least one additional therapeutic agent. | 2008-10-09 |
20080248071 | Diffusing Particles Based on Organogelling Xerogel Fibers, Method for Preparing Same and Use in Cosmetic Formulations - The invention concerns particles consisting essentially of fibers of an organogelling substance in the form of xerogel (dry gel), the fibers being essentially oriented in a common direction and randomly aligned around the longest fiber. The organogelling substance is preferably 1,3:2,4-di-O-benzylidene-D-sorbitol. Said particles, which are in the form of spindles, have interesting optical properties; they have a total light transmittance higher than 0.80, with a diffuse transmittance higher than the specular transmittance. The invention also concerns a method for preparing said particles by solvent evaporation process, by solvent diffusion/evaporation process or by shearing process. The invention finally concerns active particles consisting of said particles whereon is immobilized a dermocosmetically active principle, a dermocosmetic composition comprising said particles or said active particles and a cosmetic treatment method which consists in applying on the skin said dermocosmetic composition. | 2008-10-09 |
20080248072 | Transparent multi-phase dentifrice with patterns - A multi-phase dentifrice composition comprising at least two visually distinct phases wherein said visually distinct phases are packaged in a generally transparent container, at least one phase is in physical contact with another phase, at least one visually distinct phase is generally transparent, and the visually distinct phases form a pattern. | 2008-10-09 |
20080248073 | Opaque multi-phase dentifrice with coils - A multi-phase dentifrice composition comprising at least two visually distinct phases wherein said visually distinct phases are packaged in a generally transparent container, at least one phase is in physical contact with another phase, all visually distinct phases are opaque, and at least one visually distinct phase forms a coil through at least one other visually distinct phase. | 2008-10-09 |
20080248074 | Treatment for Topical Use in Alleviating or Inhibiting Joint Pain or Muscle Pain or Musculoskeletal Pain in a Mammal - A treatment for topical use in alleviating or inhibiting joint pain, muscle pain, or musculoskeletal pain in a mammal. The treatment includes dried nettle plant applied to the skin of a mammal, or includes liquid nettle extract applied to the skin of a mammal, or includes a textile fabric ( | 2008-10-09 |
20080248075 | Domestic Appliance - The liquid-bearing domestic appliance, in particular domestic dishwasher, is provided with at least one antibiotic agent, in particular in the sump and/or the tub and/or an insert. | 2008-10-09 |
20080248076 | ANTIMICROBIAL RUBBER BANDS - An antimicrobial vulcanized rubber article that includes at least one rubber component; and an antimicrobial agent selected from the group consisting of zinc pyrithione, zinc dimethyldithiocarbamate, and chlorhexidine base. | 2008-10-09 |
20080248077 | Formulation - The present invention relates to slow release anastrozole formulations, more particularly to biodegradable polymers, typically a polylactide or poly(lactide-co-glycolide) co-polymer, in which anastrozole is incorporated, including microparticle formulations and monolithic implant formulations. The invention also relates to methods of treatment using said formulations, particularly methods for the treatment of breast cancer. | 2008-10-09 |
20080248078 | SYSTEMS AND METHODS OF PROMOTING ENDOTHELIALIZATION OF A HYBRID HEMODIALYSIS ACCESS GRAFT OR A HYBRID FEMORAL ARTERY BYPASS GRAFT IN A MAMMAL - Hybrid synthetic grafts and embodiments of systems and methods for producing hybrid vascular grafts that can yield implantable grafts that combine synthetic grafts with living cells. Embodiments of systems can include a pressure/flow loop subsystem having an external flow loop system coupled to a specimen holder, where the pressure/flow loop subsystem is capable of adjusting at least two dynamic conditions in the specimen holder or a diameter of a specimen in the specimen holder. Embodiments of methods can promote endothelialization of a hybrid hemodialysis access graft or a hybrid femoral artery bypass graft by placing the hybrid hemodialysis access graft or the hybrid femoral artery bypass graft in a system embodiment according to tie invention under conditions effective to promote stem cells to differentiate into endothelial cells on a surface of the hybrid graft. | 2008-10-09 |
20080248079 | TISSUE AUGMENTATION DEVICES AND METHODS - Tissue augmentation devices, as well as methods of manufacturing and using the same, are disclosed. In certain embodiments, a tissue augmentation device comprises an elongate tissue penetrating member and an amount of remodelable material, wherein at least a portion of the elongate member is cannulated, and at least a portion of the amount of material is received within at least a portion of the cannulated portion of the elongate member. The elongate tissue penetrating member may provide at least one deformation that is configured to constrict portions of the amount of remodelable material received within the elongate member. In alternate embodiments, a flexible covering over an implantable biomaterial provides protection and allows an easier delivery of the biomaterial to a tissue tract. | 2008-10-09 |
20080248080 | Decelluarlized Tissue Engineered Constructs and Tissues - New methods for producing tissue engineered constructs and engineered native tissues are disclosed. The methods include producing a tissue engineered construct by growing cells in vitro on a substrate and then decellularizing the construct to produce a decellularized construct consisting largely of extracellular matrix components. The construct can be used immediately or stored until needed. The decellularized construct can be used for further tissue engineering, which may include seeding the construct with cells obtained from the intended recipient of the construct. During any of the growth phases required for production of the construct, the developing construct may be subjected to various tissue engineering steps such as application of mechanical stimuli including pulsatile forces. The methods also include producing an engineered native tissue by harvesting tissue from an animal or human, performing one or more tissue engineering steps on the tissue, and subjecting the tissue to decellularization. The decellularized, engineered native tissue may then be subjected to further tissue engineering steps. | 2008-10-09 |
20080248081 | METHOD OF TREATING CHRONIC DYSFUNCTION OF CARDIAC MUSCLE - Methods are described for using compositions containing platelet-rich plasma for the treatment of a variety of tissue lesions. Particularly, delivery of platelet-rich plasma to cardiac muscle for treatment of chronic dysfunction of cardiac muscle is disclosed. | 2008-10-09 |
20080248082 | METHOD OF TREATING INJURED CARDIAC TISSUE - Methods are described for using compositions containing platelet-rich plasma for the treatment of a variety of tissue lesions. Particularly, delivery of platelet-rich plasma to treat injured cardiac tissue is disclosed. | 2008-10-09 |
20080248083 | METHOD FOR TREATMENT OF TISSUE LESION - Methods are disclosed to promote vascularization of tissue in mammals using an autologous platelet-rich plasma composition. In particular, a method of treating a cardiac tissue lesion is disclosed. | 2008-10-09 |
20080248084 | METHOD OF TREATING ACUTE DYSFUNCTION OF CARDIAC MUSCLE - Methods are described for using compositions containing platelet-rich plasma for the treatment of a variety of tissue lesions. Particularly, delivery of platelet-rich plasma to treat acute dysfunction of cardiac muscle (heart attack) is disclosed. | 2008-10-09 |
20080248085 | METHOD OF TISSUE VASCULARIZATION - Methods are disclosed to promote vascularization of tissue in mammals using an autologous platelet-rich plasma composition. The methods are useful for vascularizing tissue with a compromised blood supply, particularly cardiac tissue with a compromised blood supply due to heart attack or congestive heart failure. | 2008-10-09 |
20080248086 | CURABLE THERAPEUTIC IMPLANT COMPOSITION - The exemplary embodiments of the present invention relates to a curable therapeutic implant composition for use in the filling of a cavity in a living organism, comprising particles of a metallic material, and a curable matrix-forming, non-particulate material, wherein at least one of the metallic material or the matrix-forming material is at least partially degradable in-vivo. Furthermore, the exemplary embodiments of the present invention relate to methods of filling a cavity in a living organism with the use of the curable implant composition. | 2008-10-09 |
20080248087 | ABSORBENT ARTICLE - An absorbent article has an absorbent material and an outer surface including an inhibitor which is partially bound to the absorbent material and substantially inhibits the colonization of bacteria within the absorbent article. | 2008-10-09 |
20080248088 | Decontaminant edible product, methods of production and uses thereof - The invention relates to an edible product containing a decontaminant. Particularly, the invention relates to an edible product, for instance, a food-like product, containing an effective amount of activated charcoal to mitigate, substantially reduce or cause the cessation of at least one adverse effect associated with the ingestion of a toxic substance. The invention also relates to methods for manufacturing such a decontaminant edible product and uses thereof. | 2008-10-09 |
20080248089 | EDIBLE PRODUCTS FOR THE TREATMENT OF NASAL PASSAGES - The present invention relates to oral delivery systems, such as confectionery and chewing gum compositions, and methods for imparting the perception of nasal clearing to a user. In particular, the present invention includes confectionery and chewing gum compositions including a compound selected from 4-pentenyl isothiocyanate, 5-hexenyl isothiocyanate, 3-butenyl isothiocyanate, 3-methylthiopropyl isothiocyanate, and any combinations thereof and methods. The delivery systems promote the perception of nasal clearing in the user. | 2008-10-09 |
20080248090 | GRADUATED CONCENTRATION SODIUM CHLORIDE PATCHES FOR THE TREATMENT OF DENTAL CONDITIONS - A plurality of patches are prepared, containing a therapeutic agent, particularly NaCl, another salt, or another type of agent, for being held in contact with a portion of the oral cavity in order to treat a dental condition. The patches have respective concentrations of NaCl such that the concentrations cover a range from substantially hypotonic to substantially hypertonic. In particular, the plurality of patches may have a corresponding plurality of respective concentrations between about 0.22% and about 25% (weight/volume). | 2008-10-09 |
20080248091 | Charge Gradient Inhibition of Trypanosoma Cruzi and Other Parasite's Invasive Action - Methods for delaying and/or preventing the binding of parasites to host cells (especially mammalian host cells) are provided. The methods delay or prevent infection of host cells and the development of disease symptoms. The methods delay or prevent the parasites from locating and binding to host cells, thereby reducing the infectivity of the parasite, and allow for adjuvant drug therapy to have a longer treatment time period before infection sets in. The methods involve modifying the charge field sensed by the parasite in the vicinity of potential host cells. Such modifications may be made by exposing the parasite and/or the host cell to charge-altering agents such as charged nanoparticles. | 2008-10-09 |
20080248092 | Formulations of Water Insoluble or Poorly Water Soluble Drugs in Lipidated Glycosaminoglycan Particles and Their Use for Diagnostic and Therapy - The invention provides a formulation of water insoluble or poorly water soluble drugs encapsulated in lipidated glycosaminoglycan particles for targeted drug delivery. | 2008-10-09 |
20080248093 | pH sensitive prodrugs of 2,6-diisopropylphenol - The present invention is directed to water-soluble derivatives of 2,6-diisopropylphenol (Propofol). The compounds act as prodrugs of 2,6-diisopropylphenol and metabolize rapidly to Propofol thereby providing an alternative to the water-insoluble 2,6-diisopropylphenol. Pharmaceutical compositions comprising these compounds, methods of induction and maintenance of anesthesia or sedation as well as methods of treating neurodegenerative diseases utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed. | 2008-10-09 |
20080248094 | VACCINE ADJUVANT PROPERTIES OF LIPSOMES FORMED AT ELEVATED TEMPERATURES FROM THE POLAR CHLOROFORM EXTRACTABLE LIPIDS FROM MYCOBACTERIUM BOVIS - The invention relates to a liposome comprising a chloroform soluble and extractable total polar lipid of Mycobacterium spp, particularly a chloroform soluble extractable total polar lipid of Mycobacterium bovis BCG. The chloroform soluble and extractable polar lipid may comprise at least one of phosphatidylinositol (PI), phosphatidylinositol mannoside (PIM | 2008-10-09 |
20080248095 | SMALL PARTICLE LIPOSOME AEROSOLS FOR DELIVERY OF ANTI-CANCER DRUGS - The small particle liposome aerosol compounds and methods of treatment of the present invention involve lipid- or water soluble anti-cancer drugs incorporated into liposomes. The liposomes are administered in aqueous dispersions from a jet nebulizer to the respiratory tract of an individual. Various anti-cancer drugs may be used, including 20-S-Camptothecin, 9-Nitro-camptothecin, 9-Amino-camptothecin, 10, 11-methylenedioxy-camptothecin and taxol or its derivatives. Administration of these drugs by inhalation provides faster and more efficient absorption of the anticancer drug than does intramuscular administration or oral administration. | 2008-10-09 |
20080248096 | SMALL PARTICLE LIPOSOME AEROSOLS FOR DELIVERY OF ANTI-CANCER DRUGS - Provided herein is a method of treating primary lung cancer or metastatic cancer to the lung in an individual by delivering at least once to the respiratory tract of the individual via inhalation a nebulized liposomal aerosol comprising a dilauroylphosphatidylcholine liposome containing camptothecin or a derivative thereof in an amount sufficient to deliver a pharmacologically effective dose of the camptothecin or its derivative to treat the cancer. Also provided is a nebulized liposomal aerosol comprising the DLPC containing the camptothecin or its derivative and a method of making the liposome-drug comprising the aerosol. | 2008-10-09 |
20080248097 | POLYMERIC MICELLES FOR COMBINATION DRUG DELIVERY - The invention provides block polymers, micelles, and micelle formulations for combination drug therapy. Polyamide block polymers, such as those of formulas I and II are useful, for example, for preparation of mixed drug micelles, including simply mixed micelles, physically mixed micelles, and chemically mixed micelles. The invention further provides methods of treating cancer, and inhibiting and killing cancer cells. Also provided are methods for the preparation of polymer drug conjugates and intermediates for their synthesis. | 2008-10-09 |
20080248098 | Polysaccharide Microparticles Containing Biological Agents: Their Preparation and Applications - A method of preparing polysaccharide glassy microparticles which are less than 10 μum in diameter and contain structurally delicate agents, such as proteins, peptides, gene materials, vaccines, antibodies, viruses and liposomes using low-temperature aqueous-aqueous emulsification (free of polyelectrolytes) and freezing-induced phase separation. When delicate agents are added to a polysaccharide-PEG two phase system followed by homogenization (or other shear adding process), the agents partition into the polysaccharide dispersed phase preferentially. These processes help to avoid aggregation of proteins caused by interaction with charged polyelectrolytes used for stabilizing the polysaccharide dispersed phase in our previously reported aqueous-aqueous emulsion. When this system is frozen and lyophilized, glassy particles less than 10 μm in diameter containing delicate agents can be formed. These fine polysaccharide particles protect proteins within their hydrophilic glassy matrix, and can therefore be easily suspended in hydrophobic polymer solutions and formulated to various forms of sustained release devices such microsphere, sheets, fibers, coating layers, and scaffolds. The particles can also be dispersed in hydrophilic gels to improve releasing kinetics and to deliver vaccines and antibodies for immune therapy. | 2008-10-09 |
20080248099 | Method for Treating Disease or Disorder of Adult Central Nervous System Associated with Tissue Shrinkage or Atrophy by Administration of Insulin - The present invention provides a use of an insulin for the manufacture of a medicament for treating or preventing diseases or disorders of adult brain. Also provided is a method for treating or preventing diseases or disorders of adult brain by administering an effective amount of an insulin to the brain. The diseases or disorders of adult brain are associated with tissue shrinkage or atrophy. The amount of the insulin administered is preferably from 0.001 Units per kg body weight per day up to 10 Units per kg body weight per day. | 2008-10-09 |
20080248100 | MAGNESIUM COMPOSITIONS AND USES THEREOF - A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of applications provided herein, such as maintaining, enhancing, and/or improving health, nutrition, and/or another condition of a subject, and/or cognitive, learning, and/or memory function. A magnesium-counter ion composition provided herein may be useful for administration to a subject presenting magnesium deficiency, mild cognitive impairment, Alzheimer's disease, attention deficit hyperactivity disorder, ALS, Parkinson's disease, diabetes, migraine, anxiety disorder, mood disorder, and/or hypertension. A kit, method, and other associated technology are also provided. | 2008-10-09 |